Bio-Techne (NASDAQ:TECH) Receives "Sector Weight" Rating from KeyCorp

Bio-Techne (NASDAQ:TECH - Get Free Report)'s stock had its "sector weight" rating reissued by analysts at KeyCorp in a research note issued on Wednesday, MarketBeat reports. KeyCorp also issued estimates for Bio-Techne's Q3 2025 earnings at $0.44 EPS and Q4 2025 earnings at $0.43 EPS.

Several other equities research analysts also recently weighed in on the company. Robert W. Baird downgraded Bio-Techne from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $88.00 to $68.00 in a report on Wednesday, February 19th. Royal Bank of Canada upped their target price on shares of Bio-Techne from $79.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 6th. Scotiabank raised their target price on shares of Bio-Techne from $88.00 to $90.00 and gave the company a "sector outperform" rating in a report on Thursday, February 6th. Evercore ISI assumed coverage on shares of Bio-Techne in a report on Tuesday, March 18th. They set an "outperform" rating and a $75.00 price target for the company. Finally, Baird R W lowered shares of Bio-Techne from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Bio-Techne has a consensus rating of "Moderate Buy" and an average price target of $81.25.

Remove Ads

Bio-Techne Stock Up 2.4 %

Shares of TECH traded up $1.20 during mid-day trading on Wednesday, hitting $51.92. 560,500 shares of the company's stock were exchanged, compared to its average volume of 1,180,584. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.77 and a current ratio of 3.94. The company has a market cap of $8.21 billion, a price-to-earnings ratio of 52.44, a P/E/G ratio of 2.88 and a beta of 1.45. The stock's 50-day moving average is $61.32 and its 200-day moving average is $69.53. Bio-Techne has a fifty-two week low of $46.44 and a fifty-two week high of $85.57.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($0.03). Bio-Techne had a return on equity of 12.73% and a net margin of 13.22%. On average, sell-side analysts anticipate that Bio-Techne will post 1.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Kim Kelderman sold 13,392 shares of Bio-Techne stock in a transaction on Monday, January 27th. The shares were sold at an average price of $77.29, for a total value of $1,035,067.68. Following the transaction, the chief executive officer now directly owns 39,004 shares of the company's stock, valued at $3,014,619.16. The trade was a 25.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Amy E. Herr sold 1,860 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $65.96, for a total transaction of $122,685.60. Following the sale, the director now owns 1,976 shares of the company's stock, valued at approximately $130,336.96. This represents a 48.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. L. Roy Papp & Associates LLP lifted its holdings in shares of Bio-Techne by 1.8% during the first quarter. L. Roy Papp & Associates LLP now owns 23,108 shares of the biotechnology company's stock worth $1,355,000 after purchasing an additional 401 shares during the period. Whipplewood Advisors LLC boosted its holdings in shares of Bio-Techne by 30,250.0% in the first quarter. Whipplewood Advisors LLC now owns 1,214 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 1,210 shares in the last quarter. Fulton Bank N.A. increased its stake in shares of Bio-Techne by 17.4% during the first quarter. Fulton Bank N.A. now owns 7,963 shares of the biotechnology company's stock worth $467,000 after acquiring an additional 1,182 shares during the period. Harbor Investment Advisory LLC raised its holdings in Bio-Techne by 529.9% during the first quarter. Harbor Investment Advisory LLC now owns 10,708 shares of the biotechnology company's stock worth $628,000 after purchasing an additional 9,008 shares in the last quarter. Finally, NBC Securities Inc. acquired a new stake in Bio-Techne in the first quarter valued at about $228,000. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.